Gala Biotech, a Catalent Pharma Solutions
Company, was established in 1996 from technology developed
at the University
of Wisconsin. Located in Middleton, Wisconsin, this rapidly
(currently over 40 employees, including 16 PhD’s) has a
wide range of capabilities in the fields of molecular biology,
biology, cell line development, biopharmaceutical manufacturing,
protein biochemistry, and quality systems. Gala’s
core proprietary technology is GPEx® (Gene Product
Expression), a gene insertion/expression technology that
of stable, high-expressing mammalian cell lines for a wide
variety of gene products.
"Gala" is Greek for milk, and the
company's original mission was to produce pharmaceutical proteins
in the milk
of transgenic cows. The gene insertion technology that Gala
developed to generate transgenic animals became the basis
of Gala's Gene Product
Expression or GPEx® technology for production
of recombinant proteins in mammalian cell culture.
The genomics revolution has led to the
identification of thousands of new genes, and the race
is now on to discover,
characterize and stably express the protein products of these
genes in order to develop new therapeutic proteins. Gala's
GPEx® technology, when applied to mammalian cell culture,
accelerates this process for its biopharmaceutical partners.
Once new therapeutic proteins have been identified for clinical
development, production support becomes a major challenge.
is to meet this need, and the company has
recently established a 43,000 square-foot facility in
Middleton, Wisconsin devoted to GPEx®-based cell line
development and cGMP-compliant protein production.